Evaluation of Different Treatment Options Used for Post Covid-19 Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Mini-Mental State Examination (MMSE)
研究概览
简要总结
This study aimed to assess functioning during the recovery phase post-COVID-19 and to evaluate symptoms prolonging after COVID-19 infection and how to manage these symptoms.
详细描述
COVID-19 is a disease caused by a new strain of coronavirus The COVID-19 virus is a new virus linked to the same family of viruses as severe acute respiratory syndrome (SARS) and some types of common cold. Symptoms can include fever, cough, and shortness of breath. In more severe cases, infection can cause pneumonia or breathing difficulties. More rarely, the disease can be fatal. These symptoms are similar to the flu (influenza) or the common cold, which are a lot more common than COVID-19.
The virus is transmitted through direct contact with respiratory droplets of an infected person (generated through coughing and sneezing). Individuals can also be infected from and touching surfaces contaminated with the virus and touching their face (e.g., eyes, nose, mouth).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged from 18 to 70 years.
- •Both sexes.
- •Positive diagnosis of COVID-19 within the last 3 months in relation to the time of assessment (COVID-19 diagnosis had been previously confirmed by RT-PCR nasal swab testing as part of routine clinical evaluation before enrollment into the study).
排除标准
- •Patients with other non-COVID-related chronic illnesses that could interfere with the assessment of post-viral symptoms.
- •Patients with pre-existing neurological disorders that could affect cognitive function or fatigue assessment, including dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, or prior cerebrovascular stroke, patients with diagnosed psychiatric disorders such as major depressive disorder, bipolar disorder, schizophrenia, or anxiety disorders requiring ongoing pharmacological treatment.
- •Patients with uncontrolled endocrine disorders, particularly uncontrolled diabetes mellitus or thyroid dysfunction.
- •Patients with malignancy or receiving chemotherapy, radiotherapy, or immunosuppressive therapy during the study period.
- •Patients with chronic fatigue syndrome, fibromyalgia, or other pre-existing fatigue-related disorders diagnosed prior to SARS-CoV-2 infection.
- •Patients with substance abuse or alcohol dependence, pregnant or lactating women.
- •Patients with known hypersensitivity or contraindications to Ginkgo biloba or piracetam.
- •Patients with poor adherence to treatment or anticipated inability to complete follow-up visits.
研究组 & 干预措施
Group I
Patients who received Ginkgo biloba alone.
干预措施: Ginkgo biloba (Drug)
Group II
Patients who received piracetam alone.
干预措施: Piracetam (Drug)
Group III
Patients who received a combination (Ginkgo biloba and Piracetam).
干预措施: Ginkgo biloba and Piracetam (Drug)
结局指标
主要结局
Mini-Mental State Examination (MMSE)
时间窗: 1 year after the procedure
The Mini-Mental State Examination (MMSE) was used to assess global cognitive status. It evaluates orientation, immediate and delayed recall, attention and calculation, language, and visuospatial construction. The total score ranges from 0 to 30, with higher scores reflecting better cognitive function. Cognitive impairment was classified as mild (21-24), moderate (10-20), or severe (\<10). The MMSE was administered in a face-to-face interview format
次要结局
- Fatigue Severity Scale(1 year after the procedure)
- Changes in headache severity(1 year after the procedure)
- Prevalence of neurological manifestations(1 year post-procedure)
- Length of hospital stay(Till the discharge from the hospital (Up to 2 weeks))
研究者
Esraa Hussien Gomaa
Bachelor degree in Pharmaceutical Sciences (Clinical Pharmacy), Beni- Suef University, Egypt.
Beni-Suef University